← SynDRA
LASMIDITAN
SynDRA canonical compound SYN0037767 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | HTR1F |
|---|
| Mechanism of action | serotonin receptor agonist |
|---|
All known targets
Mechanisms of action (all sources)
- HTR1F AGONIST
- Serotonin 1f (5-HT1f) receptor agonist
- HTR1F FULL AGONIST
- serotonin receptor agonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HTR1D
- HTR2B
- HTR7
- DRD5
- OPRK1
- SIGMAR1
- HTR1E
- TMEM97
- CHRM5
- HTR2C
- HTR3A
- NEIL1
- HTR5A
- HTR6
- HTR2A
- MPG
- MUTYH
- ADGRF1
- HTR1B
- NTHL1
- OGG1
- OPRD1
- OPRM1
- S1PR1
- SLC6A2
- SLC6A3
- SLC6A4
- SMUG1
- TDG
- NEIL2
- HRH4
- HTR1A
- ADRA1A
- ADRA1B
- ADRA1D
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
Drug classes
- Neurotransmitter Agents
- Serotonin Agents
- Serotonin Receptor Agonists
ATC classes
- N02C · ANTIMIGRAINE PREPARATIONS
Cross-references
Synonyms
- REYVOW
- Reyvow
- lasmiditan succinate
- COL-144
- LY-573144
- reyvow
- rayvow
- LY573144
- Migraine therapy, CoLucid
- COL 144
- lasmiditanum
- RefChem:58578
- DTXCID00203418
- MFCD18633238
- lasmitidan
- Lasmiditan [INN]
- Lasmiditan [USAN:INN]
- UNII-760I9WM792
- LASMIDITAN [MI]
- Lasmiditan (USAN/INN)
- LASMIDITAN [USAN]
- LASMIDITAN [WHO-DD]
- orb198469
- SCHEMBL536057
- GTPL3928
- SCHEMBL29376817
- DEA NO. 2790
- XEDHVZKDSYZQBF-UHFFFAOYSA-N
- GLXC-10055
- HMS5086L18
- ARD14625
- EX-A1300
- EX-A1653
- BDBM50573975
- s5064
- AKOS016000352
- CS-2032
- Lasmiditan; OL-144; LY573144
Reported adverse events
- Depression
- Dizziness
- Fatigue
- Headache
- Hypersensitivity
- Nausea
- Sedation
- Vomiting
Look up LASMIDITAN in the interactive SynDRA portal →